SAB Biotherapeutics, Inc. (SABS) Cash Flow Statement

The FCF trajectory shows no operating leverage offsetting the widening R&D and SG&A spend identified in the income statement review; the burn stepped from a roughly -$7M to -$11M quarterly range through early 2025 to -$17.7M, -$15.3M, and -$26.7M across the three most recent quarters. Because this outflow persists in every period irrespective of the one-time 2025Q3 net income print, the FCF line appears to be the more faithful proxy for the true economic trajectory, and the trend implies a financing requirement that investors should monitor closely.

Across the ten quarters, operating cash flow remains negative in every period even when net income is positive, indicating that reported earnings carry no cash backing and that the loss-making core operations consume liquidity regardless of accounting outcomes. The OCF/NI ratio swings from 0.61 to 2.17 across loss quarters and inverts to -0.29 in the gain quarter, underscoring that the ratio here signals structural non-conversion rather than working capital timing.

The divergence is driven both by the non-cash nature of the 2025Q3 one-time gain and by heavy non-cash charges such as stock-based compensation, which reached $12.7M in 2026Q2 alone. For an analyst, the implication is that any valuation or runway model anchored to reported net losses will systematically understate the capital required, and the worsening direction of the gap in recent quarters warrants further investigation into the composition of operating adjustments.

The inconsistent direction of working capital changes alongside steadily widening losses suggests no discernible efficiency trend in collections or payables management; the swings likely reflect lumpy accruals around the step-up in R&D activity. With revenue absent from most periods, there is no receivables or inventory cycle to analyze in the conventional sense, meaning working capital should be treated as a noise factor rather than a signal of cash discipline.

This late-cycle step-up in capex appears to coincide with the acceleration in R&D and SG&A spend, suggesting a transition from a largely virtual, outsourced development model toward greater in-house manufacturing or facility investment. If this represents growth rather than maintenance capital, the depressed historical capex base means future depreciation will rise materially, and investors should assess whether the spend generates productive assets or simply extends the cash runway requirement.

The absence of any return-of-capital program is unremarkable for a pre-commercial biotech but confirms there is no discretionary capital allocation levers available to buffer the burn. The $9K buyback in 2026Q2, trivial in the context of a -$26.7M quarterly FCF deficit, may reflect a token repurchase rather than a deliberate capital return strategy, and carries no analytical weight for return-on-investment assessment.